A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease

Bone

Volumn 77, Issue , 2015, Pages 57-68

  Paton Hough, J ^a   Chantry, A D ^a   Lawson, M A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bone disease; Multiple myeloma; Murine models; Tumour burden

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE DISEASE; CONTROLLED STUDY; CORTICAL BONE; DISEASE ASSOCIATION; DRUG EFFICACY; IMMUNOCOMPETENCE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; REVIEW; SCID MOUSE; TRABECULAR BONE; TUMOR GROWTH; XENOGRAFT; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG SCREENING; NONOBESE DIABETIC MOUSE; PATHOLOGY;

ANIMALS; BONE DISEASES; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928312854     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.04.004     Document Type: Review

References (69)

1. Rajkumar S.V., Kyle R.A. Diagnosis and treatment of multiple myeloma. Neoplastic Diseases of the Blood 2013, 637-663. Springer.
2. Lock R.B., Liem N., Farnsworth M.L., Milross C.G., Xue C., Tajbakhsh M., et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002, 99:4100-4108.
3. Cruz J.C., Alsina M., Craig F., Yoneda T., Anderson J.L., Dallas M., et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 2001, 29:441-447.
4. Huang Y.-W., Richardson J.A., Tong A.W., Zhang B.-Q., Stone M.J., Vitetta E.S. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 1993, 53:1392-1396.
5. Doran P.M., Turner R.T., Chen D., Facteau S.M., Ludvigson J.M., Khosla S., et al. Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 2004, 32:351-359.
6. Thirukkumaran C.M., Shi Z.Q., Luider J., Kopciuk K., Gao H., Bahlis N., et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res 2012, 18:4962-4972.
7. Mitsiades C.S., Mitsiades N.S., Bronson R.T., Chauhan D., Munshi N., Treon S.P., et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model biologic and clinical implications. Cancer Res 2003, 63:6689-6696.
8. Wu K.-D., Zhou L., Burtrum D., Ludwig D.L., Moore M.A. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007, 56:343-357.
9. Kikuchi J., Yamada S., Koyama D., Wada T., Nobuyoshi M., Izumi T., et al. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem 2013, 288:25593-25602.
10. Mirandola L., Yu Y., Chui K., Jenkins M.R., Cobos E., John C.M., et al. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One 2011, 6:e21811.
11. Carlo-Stella C., Guidetti A., Di Nicola M., Longoni P., Cleris L., Lavazza C., et al. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Exp Hematol 2006, 34:721-727.
12. Rabin N., Kyriakou C., Coulton L., Gallagher O., Buckle C., Benjamin R., et al. A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 2007, 21:2181-2191.
13. Swami A., Reagan M.R., Basto P., Mishima Y., Kamaly N., Glavey S., et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci 2014, 111:10287-10292.
14. Zhang Y., Moschetta M., Huynh D., Tai Y.-T., Zhang Y., Zhang W., et al. Pyk2 promotes tumor progression in multiple myeloma. Blood 2014, 124:2675.
15. Roccaro A.M., Sacco A., Purschke W.G., Moschetta M., Buchner K., Maasch C., et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 2014, 9:118-128.
16. Azab A.K., Sahin I., Azab F., Moschetta M., Mishima Y., Burwick N., et al. CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood 2014, 124(12):1905-1914.
17. Pilarski L.M., Hipperson G., Seeberger K., Pruski E., Coupland R.W., Belch A.R. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95:1056-1065.
18. Hiramatsu H., Nishikomori R., Heike T., Ito M., Kobayashi K., Katamura K., et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood 2003, 102:873-880.
19. Sanchez P.V., Perry R.L., Sarry J.E., Perl A.E., Murphy K., Swider C.R., et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009, 23:2109-2117.
20. nullNOG) mice. Biochem Biophys Res Commun 2004, 313:258-262.
21. Dewan M., Watanabe M., Terashima K., Aoki M., Sata T., Honda M., et al. Prompt tumor formation and maintenance of constitutive NF-κB activity of multiple myeloma cells in NOD/SCID/γCnull mice. Cancer Sci 2004, 95:564-568.
22. Lawson M.A., Paton-Hough J.M., Evans H.R., Walker R.E., Harris W., Ratnabalan D., et al. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. PLoS One 2015, 10:e0119546.
23. Fuhler G.M., Brooks R., Toms B., Iyer S., Gengo E.A., Park M.Y., et al. Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med 2012, 18:65-75.
24. Bartee E., Chan W.M., Moreb J.S., Cogle C.R., McFadden G. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant 2012, 18:1540-1551.
25. Iriuchishima H., Takubo K., Miyakawa Y., Nakamura-Ishizu A., Miyauchi Y., Fujita N., et al. Neovascular niche for human myeloma cells in immunodeficient mouse bone. PLoS One 2012, 7:e30557.
26. Schueler J., Wider D., Klingner K., Siegers G.M., May A.M., Wäsch R., et al. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ (null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PLoS One 2013, 8:e79939.
27. Hurchla M.A., Garcia-Gomez A., Hornick M.C., Ocio E.M., Li A., Blanco J.F., et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013, 27:430-440.
28. Udi J., Schüler J., Wider D., Ihorst G., Catusse J., Waldschmidt J., et al. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br J Haematol 2013, 161:104-116.
29. Tassone P., Neri P., Carrasco D.R., Burger R., Goldmacher V.S., Fram R., et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005, 106:713-716.
30. Tassone P., Neri P., Burger R., Savino R., Shammas M., Catley L., et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005, 11:4251-4258.
31. Urashima M., Chen B.P., Chen S., Pinkus G.S., Bronson R.T., Dedera D.A., et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997, 90:754-765.
32. Yaccoby S., Pearse R.N., Johnson C.L., Barlogie B., Choi Y., Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002, 116:278-290.
33. Yaccoby S., Barlogie B., Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998, 92:2908-2913.
34. Yata K., Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004, 18:1891-1897.
35. Pennisi A., Li X., Ling W., Khan S., Zangari M., Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009, 84:6-14.
36. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
37. Calimeri T., Battista E., Conforti F., Neri P., Di Martino M., Rossi M., et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011, 25:707.
38. Radl J., De Glopper E., Schuit H.R., Zurcher C. Idiopathic paraproteinemia II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979, 122:609-613.
39. Vanderkerken K., De Raeve H., Goes E., Van Meirvenne S., Radl J., Van Riet I., et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997, 76:451.
40. Croucher P.I., De Raeve H., Perry M.J., Hijzen A., Shipman C.M., Lippitt J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003, 18:482-492.
41. Menu E., De Leenheer E., De Raeve H., Coulton L., Imanishi T., Miyashita K., et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006, 23:291-300.
42. Asosingh K., Radl J., Van Riet I., Van Camp B., Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000, 1:351-356.
43. Heath D.J., Chantry A.D., Buckle C.H., Coulton L., Shaughnessy J.D., Evans H.R., et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009, 24:425-436.
44. Deleu S., Lemaire M., Arts J., Menu E., Van Valckenborgh E., King P., et al. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 2009, 23:1894-1903.
45. Menu E., Asosingh K., Indraccolo S., De Raeve H., Van Riet I., Van Valckenborgh E., et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006, 91:605-612.
46. Menu E., Jernberg Wiklund H., De Raeve H., De Leenheer E., Coulton L., Gallagher O., et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 2007, 121:1857-1861.
47. Croucher P.I., Shipman C.M., Lippitt J., Perry M., Asosingh K., Hijzen A., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001, 98:3534-3540.
48. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003, 63:287-289.
49. Alici E., Konstantinidis K.V., Aints A., Dilber M.S., Abedi-Valugerdi M. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma. Exp Hematol 2004, 32:1064-1072.
50. Gouard S., Pallardy A., Gaschet J., Faivre-Chauvet A., Bruchertseifer F., Morgenstern A., et al. Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and melphalan chemotherapy. Nucl Med Biol 2014, 41S:e30-e35.
51. Xu D., Hu J., De Bruyne E., Menu E., Schots R., Vanderkerken K., et al. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun 2012, 428:518-524.
52. Khong T., Sharkey J., Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 2008, 93:860-869.
53. Caers J., Menu E., De Raeve H., Lepage D., Van Valckenborgh E., Van Camp B., et al. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br J Cancer 2008, 98:1966-1974.
54. Lemaire M., Fristedt C., Agarwal P., Menu E., Van Valckenborgh E., De Bruyne E., et al. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Clin Cancer Res 2012, 18:2230-2239.
55. Garrett I., Dallas S., Radl J., Mundy G. A murine model of human myeloma bone disease. Bone 1997, 20:515-520.
56. Dallas S.L., Garrett I.R., Oyajobi B.O., Dallas M.R., Boyce B.F., Bauss F., et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697-1706.
57. Oyajobi B.O., Muñoz S., Kakonen R., Williams P.J., Gupta A., Wideman C.L., et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 2007, 6:1701-1708.
58. Bera S., Greiner S., Choudhury A., Dispenzieri A., Spitz D.R., Russell S.J., et al. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia 2010, 12:980-992.
59. Otjacques E., Binsfeld M., Rocks N., Blacher S., Vanderkerken K., Noel A., et al. Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors. PLoS One 2013, 8:e62818.
60. Hong S., Qian J., Li H., Yang J., Lu Y., Zheng Y., et al. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 2012, 61:561-571.
61. Mori Y., Shimizu N., Dallas M., Niewolna M., Story B., Williams P.J., et al. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004, 104:2149-2154.
62. Dairaghi D.J., Oyajobi B.O., Gupta A., McCluskey B., Miao S., Powers J.P., et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 2012, 120:1449-1457.
63. Oyajobi B.O., Franchin G., Williams P.J., Pulkrabek D., Gupta A., Munoz S., et al. Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003, 102:311-319.
64. Hofgaard P.O., Jodal H.C., Bommert K., Huard B., Caers J., Carlsen H., et al. A novel mouse model for multiple myeloma (MOPC315. BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One 2012, 7:e51892.
65. Schwarzer R., Nickel N., Godau J., Willie B.M., Duda G.N., Schwarzer R., et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J 2014, 4:e217.
66. Cheung W.C., Kim J.S., Linden M., Peng L., Van Ness B., Polakiewicz R.D., et al. Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. J Clin Invest 2004, 113:1763-1773.
67. Chesi M., Robbiani D.F., Sebag M., Chng W.J., Affer M., Tiedemann R., et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13:167-180.
68. Carrasco D.R., Sukhdeo K., Protopopova M., Sinha R., Enos M., Carrasco D.E., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11:349-360.
69. Zhang J., Zhong Y. Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal. Hematol Oncol 2014 Jan 7, [Epub ahead of print]. 10.1002/hon.2126.